View : 90 Download: 33

Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody

Title
Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody
Authors
Lee, JiyunLee, Su JinKim, KyungKim, Seung TaeLee, Jeeyun
Ewha Authors
이수진
Issue Date
2019
Journal Title
BMC CANCER
ISSN
1471-2407JCR Link
Citation
BMC CANCER vol. 19, no. 1
Keywords
MelanomaPD-1GenomicBiomarker
Publisher
BMC
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Background Clinical features of Asian melanoma patients are distinct from those of Western patients. This study was designed to determine the molecular and clinical characteristics of Asian melanoma patients treated with anti-PD-1 antibody. Methods Patients with recurrent or metastatic melanoma who began anti-PD-1 antibody therapy between January 2015 and April 2018 were retrospectively reviewed. Patients who underwent next-generation sequencing were also analyzed. Results A total of 152 patients were included. The median age was 61 years, and 53% of patients were female. A total of 56 patients (37%) received immunotherapy as second-line or greater chemotherapy. Primary sites were acral (38%), mucosal (31%), cutaneous (24%), uveal (2%), and unknown (5%). The overall response rate was 17% (95% CI, 11-22%), and disease control rate was 60% (95% CI, 52-68%). The median progression-free survival (PFS) was 4.2 months (95% CI, 1.8-6.6 months), and median overall survival (OS) was 32.9 months (95% CI, 20.0-45.7 months). However, BRAF(V600) and KIT mutational statuses were not associated with response or survival. High neutrophil-lymphocyte ratio (NLR) was associated with poor PFS (median PFS 6.9 vs. 2.4 months, p = 0.015) and OS (median OS NR vs. 10.4 months, p < 0.001). In multivariate analysis, high NLR independently predicted poor survival. Conclusion This study includes the largest set of integrated genomic data analyzing Asian patients with melanoma treated with immunotherapy. BRAF(V600) and KIT mutational statuses were not associated with response or survival, and high NLR was a strong predictor of poor response to and survival with anti-PD-1 therapy.
DOI
10.1186/s12885-019-6030-5
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
Comprehensive molecular.pdf(491.87 kB) Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE